Pharmaceutical composition containing decoy and use of the same

Abstract

A pharmaceutical composition is provided for treatment and / or prevention of a disease, a disorder and / or a condition caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

Description

BACKGROUND OF THE INVENTION [0001] 1. Field of the Invention [0002] The present invention relates to a composition comprising a compound (e.g., a nucleic acid and a homolog thereof) which specifically binds to a site on a chromosome, to which site a transcriptional regulatory factor binds, and a method of using the same. More particularly, the present invention relates to a composition comprising a decoy compound and a method of using the same. [0003] 2. Description of the Related Art [0004] A variety of diseases including asthma, cancers, heart diseases, aneurysms, autoimmune diseases, and viral infections manifest varying symptoms and signs and yet it has been suggested that an abnormal expression (an overexpression or underexpression) of one or a few proteins is a major etiologic factor in many cases. In general, the expression of those proteins is controlled by a variety of transcriptional regulatory factors such as transcription activating factors and transcription suppressing ...

AI Technical Summary

Benefits of technology

[0053]FIG. 12 shows the result indicating an effect of the pharmaceutical composition of the present invention in a bronchial alveolar lavage fluid in ovalbumin-challenged animals. FIGS. 12A and 12B show the fundamental data for eosinophil counts. FIG. 12C shows effects of the invention. From the left, the bars indicate control, ovalbumin challenge, aerosol treatment (2 mg×2), and liquid treatment (0.5 mg×1).

[0054]FIG. 13 shows the result indicating an effect of the pharmaceutical composition of the present invention in a bronchial alveolar lavage fluid in ovalbumin-challenged animals. FIGS. 13A (eosinophil cell counts) and 13B (eosinophil %) show effects of the invention. From the left, the bars indicate control, ovalbumin challenge, naked decoy 500 μg, HVJ (200) (containing 10000 HAU of HVJ-E and 200 μg of decoy), HVJ (500) (containing 25000 HAU of HVJ-E and 500 μg of decoy), and vector (containing only 25000 HAU of HVJ-E, no decoy). # indicates the statistical significance of ovalbumin challenge.

[0055]FIG. 14 shows an exemplary behavior of eosinophils by decoy treatments.

[0056] These and other advantages of the present invention will become apparent to those skilled in the art upon reading and understanding the following detailed description with reference to the accompanying figures. DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0057] It should be understood throughout the present specification that expression of a singular form includes the concept of their plurality unless otherwise mentioned. Specifically, articles for a singular form (e.g., “a”, “an”, “the”, etc.) include the concept of their plurality unless otherwise mentioned. It should be also understood that the terms as used herein have definitions typically used in the art unless otherwise mentioned. Thus, unless otherwise defined, all scientific and technical terms have the same meanings as those generally used by those skilled in the art to which the present invention pertain. If there is contradiction, the present specification (including the definition) takes precedence.

Problems solved by technology

Aortic aneurysmal rupture is substantially fatal.

However, it is difficult to eliminate the risk factors.

However, systemic administration of a MMP inhibitor causes severe side effects, and has difficulty in clinical applications for treatment (therapy and prevention) of various diseases.

Although a number of patients suffer from asthma, such as bronchial asthma, allergic asthma, childhood asthma, steroid-resistant asthma (SRA), and the like, it is difficult to curatively treat the disease.

However, such symptomatic treatment is only performed after attacks.

Therefore, the symptom of the patient cannot be completely prevented, much less cured.

However, no method for effectively treating these diseases, particularly a non-invasive treatment method, has been provided.

As society ages, an increase in arteriosclerotic diseases inevitably leads to an increase in aortic aneurysm diseases.

Images